Avaliação da ação antimutagênica da ipriflavonacontra os danos induzidos por ciclofosfamida
Nenhuma Miniatura disponível
Arquivos
Data
2012-05-05
Autores
Delarmelina, Juliana Macedo
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal do Espírito Santo
Resumo
Ipriflavone is a synthetic isoflavone derivative from daidzein and clinically prescribed for treating and preventing osteoporosis in postmenopausal women. We investigated the potential of this drug against the cytotoxic and mutagenic effects induced by cyclophosphamide (CPA) chemotherapy, using the micronucleus assay in bone marrow erythrocytes of Swiss albino mice (Mus musculus) in vivo. To evaluate their possible mechanisms of action, performed the evaluation of antioxidant activity by DPPH assay. For in vivo testing was carried out three protocols: pretreatment, simultaneous treatment and post treatment. The ipriflavone was evaluated in three different concentrations dissolved in DMSO (1,71; 8,57 e 42,85mg.kg-1 m.c) and administered by oral via. The bone marrow was collected for the evaluation of polycromatic erythrocytes (PCE) and the ratio PCE/(PCE+NCE) (polychromatic erythrocytes / polychromatic erythrocytes + normochromatic erythrocytes). For the DPPH test were assessed five concentrations of ipriflavone (500, 250, 150, 50 e 10μg.mLˉ¹) using DPPH solution (60μM). The results of in vivo tests show that the three concentrations of ipriflavone studied significantly reduced the frequency of MNPCEs induced by CPA, in the pre-treatment protocol and demonstrated the same effect at the concentrations of 1,71 e 42,85mg.kg-1 m.c in the post-treatment. However, simultaneous treatment did not reduce the frequency of MNPCE in any of the concentrations tested. In all protocols performed, the ratio PCE/(PCE+NCE) increased. There was variation between the genders in some of the experimental groups and the evaluation of antioxidant activity of ipriflavone showed no ability to donate hydrogens, suggesting that it acts through other mechanisms, such as inactivation of the enzyme activity of cytochrome P-450.
Descrição
Palavras-chave
Ipriflavone , Antimutagenicity , Cyclophosphamide , Micronucleus assay , Ipriflavona , Antimutagenicidade , Ciclofosfamida , Ensaio do micronúcleo , DPPH
Citação
DELARMELINA, Juliana Macedo. Avaliação da ação antimutagênica da ipriflavonacontra os danos induzidos por ciclofosfamida. 2012. 84 f. Dissertação (Mestrado em Biotecnologia) - Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Espírito Santo, Vitória, 2012.